{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The relationship between overall response rate (ORR) and Fcy receptor status. A two-sided chi-square test or exact test with α = 0.05 will be used to test the homogeneity of the ORR among the three genotypes.","groups":[{"description":"Phase I: patients receive Veltuzumab IV weekly on day 1 for 4 doses and Milatuzumab weekly for total of 4 doses during induction therapy. Induction therapy during week 1 patients receive Veltuzumab alone on day 1 and Milatuzumab alone on day 2 to prevent overlapping infusion reactions. Week 2 Veltuzumab on day 1 and Milatuzumab on day 4.\n\nPhase II: patients receive Veltuzumab IV weekly for 4 doses and Milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy.","id":"OG000","title":"All Patients From Phase I and Phase II"}],"populationDescription":"This data is not available due to analysis was not performed. The response rate was to low for the analysis to yield results to report for this trial.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Fcγ-receptor Polymorphism Response to Treatment","type":"SECONDARY"}